stockrowNational Research Corporation
NRC Healthcare Health Information Services
National Research Corporation’s revenue for fiscal 2025 (year ended December 2025) was $137.4 million, down 3.96% from fiscal 2024.
- Revenue
- +11.0%
- EPS
- +20.3%
- Free cash flow
- −31.4%
- Total debt
- +29.1%
Quarter to September 2026, against a year earlier
Follow NRC
Alert me
National Research Corporation (NRC) EV/Sales
As of 6 November 2026, National Research Corporation (NRC) trades at a EV/Sales of 4.6×. Over the past ten years it has ranged from 2.0× (April 2025) to 13.8× (January 2020); the current reading is higher than 40% of that period. That is above the Health Information Services industry median of 2.3× and above the Healthcare sector median of 3.6×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 3.6× | 8.37% |
| FY2024 | 3.3× | (52.61%) |
| FY2023 | 7.0× | 9.53% |
| FY2022 | 6.4× | (8.16%) |
| FY2021 | 6.9× | (13.32%) |
| FY2020 | 8.0× | (38.18%) |
| FY2019 | 12.9× | 46.54% |
| FY2018 | 8.8× | 20.54% |
| FY2017 | 7.3× | 88.93% |
| FY2016 | 3.9× | 13.22% |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Sep 2026 | 3.9× | (3.09%) |
| Jun 2026 | 4.0× | 25.00% |
| Mar 2026 | 3.2× | (10.87%) |
| Dec 2025 | 3.6× | 39.40% |
| 43 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| EVH Evolent Health, Inc compare | 0.6× |
| PHR Phreesia, Inc. compare | 1.7× |
| GDRX GoodRx Holdings, Inc. compare | 1.8× |
| OMDA Omada Health, Inc. compare | 2.1× |
| HSTM HealthStream, Inc. compare | 2.3× |
| NRC National Research Corporation | 4.6× |
| CARL Carlsmed, Inc. compare | 5.0× |
| CTEV Claritev Corporation compare | 5.1× |
| SOPH SOPHiA GENETICS SA compare | 6.2× |
| Health Information Services industry median | 2.3× |
| Healthcare sector median | 3.6× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)